Content validity of the PedsQL™ 3.2 Diabetes Module in newly diagnosed patients with Type 1 diabetes mellitus ages 8-45

Quality of Life Research

Volumn 22, Issue 8, 2013, Pages 2169-2181

  Varni, James W ^a   Curtis, Bradley H ^b   Abetz, Linda N ^c   Lasch, Kathryn E ^c   Piault, Elisabeth C ^c   Zeytoonjian, Andrea A ^c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MAPI VALUES   (United States)

Author keywords

Adults; Diabetes; Patient reported outcomes; Pediatrics; PedsQL; Quality of Life; Type 1

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CAREGIVER; CHILD; FEMALE; HEALTH STATUS INDICATOR; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERVIEW; MALE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PARENT; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; CAREGIVERS; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PARENTS; PATIENT OUTCOME ASSESSMENT; PSYCHOMETRICS; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; UNITED STATES; YOUNG ADULT;

EID: 84889100902     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-012-0339-8     Document Type: Article

References (49)

1. A.D.A. (2009). Type 1 Diabetes. American Diabetes Association (ADA) Website.
2. Kyvik, K. O.; Nystrom, L.; Gorus, F.; Songini, M.; Oestman, J.; Castell, C.; et al. (2004). The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia, 47, 377-384.
3. Soltesz, G.; Patterson, C. C.; & Dahlquist, G. (2007). Worldwide childhood type 1 diabetes incidence: What can we learn from epidemiology? Pediatric Diabetes, 8(Suppl), 6-14.
4. Van Belle, T. L.; Coppieters, K. T.; & von Herrath, M. G. (2011). Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiological Reviews, 91, 79-118.
5. Bott, U.; Muhlhauser, I.; Overmann, H.; & Berger, M. (1998). Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care, 21, 757-769.
6. Tierney, S.; Webb, K.; Jones, A.; Dodd, M.; McKenna, D.; Rowe, R.; et al. (2008). Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring health-related quality of life and patients' reported experiences of hypoglycaemia. Chronic Illness, 4, 278-288.
7. FDA. (2009). Guidance for Industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Food and Drug Administration. Rockville, MD: U.S. Department of Health and Human Services.
8. Varni, J. W.; Seid, M.; & Rode, C. A. (1999). The PedsQL™: Measurement model for the pediatric quality of life inventory. Medical Care, 37, 126-139.
9. Varni, J. W.; Seid, M.; & Kurtin, P. S. (2001). PedsQL™ 4.0: Reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in healthy and patient populations. Medical Care, 39, 800-812.
10. Varni, J. W.; & Limbers, C. A. (2009). The pediatric quality of life inventory™: Measuring pediatric health-related quality of life from the perspective of children and their parents. Pediatric Clinics of North America, 56, 843-863.
11. Varni, J. W.; Burwinkle, T. M.; Jacobs, J. R.; Gottschalk, M.; Kaufman, F.; & Jones, K. L. (2003). The PedsQL™ in Type 1 and Type 2 diabetes: Reliability and validity of the Pediatric Quality of Life Inventory™ Generic Core Scales and Type 1 Diabetes Module. Diabetes Care, 26, 631-637.
12. Aday, L. A. (1996). Designing and conducting health surveys: A comprehensive guide (2nd ed.). San Francisco: Jossey-Bass.
13. Fowler, F. J. (1995). Improving survey questions: Design and evaluation. Thousand Oaks, CA: Sage.
14. Schwarz, N.; & Sudman, N. (Eds.). (1996). Answering questions: Methodology for determining cognitive and communicative processes in survey research. San Francisco: Jossey-Bass.
15. Lawrence, J. M.; Yi-Frazier, J. P.; Black, M. H.; Anderson, A.; Hood, K.; Imperatore, G.; et al. (2012). Demographic and clinical correlates of diabetes-related quality of life among youth with type 1 diabetes. Journal of Pediatrics, 161, 201-207.
16. Weissberg-Benchell, J.; Nansel, T.; Holmbeck, G.; Chen, R.; Anderson, B.; Wysocki, T.; & Laffel, L. (2009). Generic and diabetes-specific parent-child behaviors and quality of life among youth with Type 1 Diabetes. Journal of Pediatric Psychology, 34, 977-988.
17. Ingerski, L. M.; Laffel, L.; Drotar, D.; Repaske, D.; & Hood, K. K. (2010). Correlates of glycemic control and quality of life outcomes in adolescents with type 1 diabetes. Pediatric Diabetes, 11, 563-571.
18. Kalyva, E.; Malakonaki, E.; Eiser, C.; & Mamoulakis, D. (2011). Health-related quality of life (HRQoL) of children with type 1 diabetes mellitus (T1DM): Self and parental perceptions. Pediatric Diabetes, 12, 34-40.
19. Nansel, T. R.; Weisberg-Benchell, J.; Wysocki, T.; Laffel, L.; & Anderson, B. (2008). Quality of life in children with Type 1 diabetes: A comparison of general and disease-specific measures and support for a unitary diabetes quality of life construct. Diabetic Medicine, 25, 1316-1323.
20. Rothman, M.; Burke, L.; Erickson, P.; Leidy, N. K.; Patrick, D. L.; & Petrie, C. D. (2009). Use of existing patient-reported outcome (PRO) instruments and their modification: The ISPOR Good Research Practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO Task Force Report. Value in Health, 12, 1075-1083.
21. Lasch, K. E.; Marquis, P.; Vigneux, M.; Abetz, L.; Arnould, B.; Bayliss, M.; et al. (2010). PRO development: Rigorous qualitative research as the crucial foundation. Quality of Life Research, 19, 1087-1096.
22. Brod, M.; Tesler, L. E.; & Christensen, T. L. (2009). Qualitative research and content validity: Developing best practices based on science and experience. Quality of Life Research, 18, 1263-1278.
23. Patrick, D. L.; Burke, L. B.; Gwaltney, C. J.; Leidy, N. K.; Martin, M. L.; Molsen, E.; et al. (2011). Content validity - Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1 - Eliciting concepts for a new PRO Instrument. Value in Health, 14, 967-977.
24. Patrick, D. L.; Burke, L. B.; Gwaltney, C. J.; Leidy, N. K.; Martin, M. L.; Molsen, E.; et al. (2011). Content validity - Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2 - Assessing respondent understanding. Value in Health, 14, 978-988.
25. Ericsson, K. A.; & Simon, H. A. (1993). Protocol Analysis: Verbal reports as data. Cambridge, MA: MIT Press.
26. Willis, G. B. (2005). Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks, CA: Sage Publications.
27. Charmaz, K. (1995). Grounded theory. In J. A. Smith, R. Harre, & L. Van Langenhove (Eds.), Rethinking methods in psychology (pp. 27-49). London: Sage.
28. Glaser, B.; & Strauss, A. L. (1967). Discovery of Grounded Theory: Strategies for Qualitative Research. New York: Aldine de Gruyter.
29. Strauss, A.; & Corbin, J. (1998). Basics of qualitative research: Techniques and procedures for developing grounded theory. London: Sage.
30. Friese, S. (2011). ATLAS.ti 6 user manual. Berlin: ATLAS.ti Scientific Software Development.
31. Weitzman, E. A.; & Miles, M. B. (1995). Computer programs for qualitative data analysis. London: Sage Publications.
32. Morse, J. M. (1995). The significance of saturation. Qualitative Health Research, 5, 147-149.
33. Guest, G.; Bunce, A.; & Johnson, L. (2006). How many interviews are enough? An experiment with data saturation and variability. Field Methods, 18, 59-82.
34. Kaas, A.; Pfleger, C.; Kharagjitsingh, A. V.; Schloot, N. C.; Hansen, L.; Buschard, K.; et al. (2012). Association between age, IL-10, IFNc, stimulated C-peptide and disease progression in children with newly diagnosed Type 1 diabetes. Diabetic Medicine, 29, 734-741.
35. Schwartz, D. D.; Axelrad, M. E.; Cline, V. D.; & Anderson, B. J. (2011). Feasibility, acceptability, and predictive validity of a psychosocial screening program for children and youth newly diagnosed with type 1 diabetes. Diabetes Care, 34, 326-331.
36. Szypowska, A.; & Skorka, A. (2011). The risk factors of ketoacidosis in children with newly diagnosed type 1 diabetes mellitus. Pediatric Diabetes, 12, 302-306.
37. Mortensen, H. B.; Swift, P. G.; Holl, R. W.; Hougaard, P.; Hansen, L.; Bjoerndalen, H.; et al. (2010). Multinational study in children and adolescents with newly diagnosed type 1 diabetes: Association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatric Diabetes, 11, 218-226.
38. Smith-Palmer, J.; Curtis, B. H.; Boye, K. S.; Goodall, G.; & Pillemer, S. R. (2010). Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: A hypothetical modelling analysis. Diabetic Medicine, 27, 189-196.
39. Martin, S.; Herder, C.; Schloot, N. C.; Koenig, W.; Heise, T.; Heinemann, L.; et al. (2011). Residual beta cell function in newly diagnosed Type 1 diabetes after treatment with Atorvastatin: The randomized DIATOR trial. PLoS ONE, 6(3), e17554.
40. Sumpter, K. M.; Adhikari, S.; Grishman, E. K.; & White, P. C. (2011). Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. Pediatric Diabetes, 12, 656-667.
41. Lachin, J. M.; McGee, P. L.; Greenbaum, C. J.; Palmer, J.; Pescovitz, M. D.; Gottlieb, P.; et al. (2011). Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed Type 1 diabetes. PLoS ONE, 6(11), e26471.
42. Tiberg, I.; Katarina, S. C.; Carlsson, A.; & Hallström, I. (2012). Children diagnosed with type 1 diabetes: A randomized controlled trial comparing hospital versus home-based care. Acta Paediatrica, 101, 1069-1073.
43. Mastrandrea, L.; Albini, C.; Yu, J.; Fourtner, S.; Behrens, T.; Quattrin, T.; et al. (2009). Etanercept treatment in children with new-onset Type 1 diabetes: Pilot randomized, placebo-controlled, double-blind study. Diabetes Care, 32, 1244-1249.
44. Hassan, K.; Rodriguez, L. M.; Johnson, S. E.; Tadlock, S.; & Heptulla, R. A. (2008). A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine hagedorn (NPH) therapy in newly diagnosed Type 1 diabetes. Pediatrics, 121, e466-e472.
45. Ludvigsson, J.; Faresjö, M.; Hjorth, M.; Axelsson, S.; Chéramy, M.; Pihl, M.; et al. (2008). GAD treatment and insulin secretion in recent-onset Type 1 diabetes. New England Journal of Medicine, 359, 1909-1920.
46. Tahirovi, H.; Toromanovi, A.; Tahirovi, E.; Begi, H.; & Varni, J. W. (2012). Health-related quality of life and metabolic control in children with Type 1 Diabetes Mellitus in Bosnia and Herzegovina. Collegium Antropologicum, 36, 117-121.
47. Sand, P.; Kljajić, M.; Schaller, J.; & Forsander, G. (2012). The reliability of the health related quality of life questionnaire PedsQL 3.0 Diabetes Module for Swedish children with Type 1 diabetes. Acta Paediatrica, 101, e344-e349.
48. Piaget, J. (1960). The child's conception of physical causality. Totowa: Littlefield, Adams and Company.
49. Scarr, S.; Weinberg, R. A.; & Levine, A. (1986). Understanding development. Orlando: Harcourt Brace Jovanovich.